Manhattan BioSolutions secures non-dilutive angel funding

by Mbio2018|Published May 1, 2018

EVQLV and Manhattan BioSolutions Enter into Strategic Collaboration to Discover Novel Antibody-Based Therapies

New York, NY August 25, 2020—EVQLV, Inc., an artificial intelligence-enabled technology company accelerating biologics discovery, announced today a strategic research collaboration with […]

Published May 12, 2020

Nascent Biotech and Manhattan BioSolutions Enter into Collaboration to Advance Vaccine Discovery and Development for COVID-19

San Diego, CA, May 12, 2020—Nascent Biotech, Inc (OTCQB: NBIO), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat cancers […]

Published May 8, 2025

Manhattan BioSolutions’ TxD ADC Collaboration Secures REACH Award from the New York Center for Biotechnology at the Stony Brook University

Published April 9, 2024

Manhattan BioSolutions, Inc. Announces Collaborative Poster Presentation on Novel FGFR4-Targeted ADC at AACR Annual Meeting 2024

Back to post list
Next post Manhattan BioSolutions has been awarded REACH grant from the New York State Center For Biotechnology at the Stony Brook University